Clinical Trials

5 enrolled 13 charts

Lymphoma, Follicular

NCT02332980 2024-01-03

Pembrolizumab Alone or With Idelalisib or Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Other Low-Grade B-Cell Non-Hodgkin Lymphomas

65 enrolled 21 charts

Lymphoma, Follicular, Waldenstrom Macroglobulinemia, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell, Lymphoma, B-Cell, Marginal Zone

NCT04699461 2023-10-23

LOTIS-6

6 enrolled 9 charts

Lymphoma, Lymphoma, Follicular

NCT02962401 2023-08-29

RemodelWM3

50 enrolled

Waldenstrom Macroglobulinemia

NCT05725200 2023-02-21

EVIDENT

Phase 2 Recruiting

40 enrolled

Gastrointestinal

Colorectal Neoplasms

NCT02968563 2022-01-21

Study to Evaluate the Safety and Efficacy of the Combination of Tirabrutinib and Idelalisib With and Without Obinutuzumab in Adults With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)

35 enrolled 12 charts

Leukemia, Lymphocytic, Chronic, B-Cell

NCT02639910 2021-12-20

COSMOS

24 enrolled 13 charts

Leukemia, Lymphocytic, Chronic, B-Cell

NCT01620216 2021-11-04

Targeted Therapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia or Acute Myelogenous Leukemia

12 enrolled 12 charts

Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT03576443 2021-10-13

ILIAD

36 enrolled

Lymphoma, Large B-Cell, Diffuse

NCT01796470 2020-06-02

Entospletinib in Combination With Idelalisib in Adults With Relapsed or Refractory Hematologic Malignancies

66 enrolled 14 charts

Leukemia, Lymphoma, Waldenstrom Macroglobulinemia, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Mantle-Cell

NCT01282424 2019-07-11

DELTA

125 enrolled 25 charts

Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Waldenstrom Macroglobulinemia, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell, Marginal Zone

NCT02258529 2019-05-14

Idelalisib in Combination With Rituximab for Previously Untreated Follicular Lymphoma and Small Lymphocytic Lymphoma

10 enrolled 10 charts

Lymphoma, Follicular, Neoplasms, Leukemia, Lymphocytic, Chronic, B-Cell

NCT01393106 2018-11-19

Safety and Efficacy of Idelalisib in Relapsed or Refractory Hodgkin Lymphoma

25 enrolled 22 charts

Hodgkin Disease

NCT02044822 2018-11-19

Efficacy and Safety of Idelalisib in Combination With Rituximab in Patients With Previously Untreated Chronic Lymphocytic Leukemia With 17p Deletion

102 enrolled 8 charts

Leukemia, Lymphocytic, Chronic, B-Cell

NCT02439138 2017-01-11

Study of Phosphatidylinositol-3-kinase (PI3K) Inhibitor Idelalisib (GS-1101) in Waldenström Macroglobulinemia

5 enrolled 8 charts

Waldenstrom Macroglobulinemia

NCT01659047 2012-09-07

A Phase 2, Single-Arm, Open-Label Study Evaluating the Efficacy and Safety of Single Agent GS 1101 (CAL 101) as Therapy for Previously Treated Chronic Lymphocytic Leukemia

Phase 2 Withdrawn